ABSTRACT
Introduction: Oncohematological patients (OHP) with Covid19 (C19) can develop serious and lethal complications. It depends on underlying disease, chemotherapy (ChT) and immunosuppressor (IS) prescribed. Objectives: compare mortality (M) in OHP vs. hospitalized normal hosts (NH);analyze independent risk factors (IRFs) of M. Methods: 3/2020-5/2022;population: OHP with C19. Prospective, observational data collection. Clinical presentation: NIH scale;Active treatment (AT): IS or ChT;Complete C19 vaccination (CV). Statistics: ANOVA and Tukey's post hoc tests for comparison of groups. Multivariate test to analyze IRFs associated with M. Results: OHP: 62;MM: 19.3%;LLC: 21%;Lymphomas: 24.2%;ALL: 11.3%;AML: 9.7%;MDS: 14.5%. Age: 68 (17-88);Male sex: 77.4%;moderate CAP: 72.6%;Severe CAP: 27.4%;CV: 22.6%;neutropenia (NP): 22.6%;AT: 61.3%. MM was associated with higher M. OD: 5.3 (95% CI 1.1742 -24.1685). OH had higher M statistically significant difference (SSD)- vs. ICP (12/62): 19% vs. (118/1168): 10%;p: 0.02. Multivariate analysis adjusted for age and sex: MM (OR: 5.32, 95% CI: 1.1742-24.1685) and Severe CAP (OD: 11.23, 95% CI: 2.0636 - 61.1310) were IRFs associated with M. AT (OR: 3.2) and NP (OR: 4.18) had higher risk of M with nonSSD;CV (OR: 0.66 95% CI 0.1110-4.0235) had lower risk without SSD. Conclusions: MM and severe CAP were IRFs for M. CAP was associated with higher M in OHP than NH. CV could be a protective factor without SSD. The high M documented in OHP with C19 justifies implementation of early preventive measures and treatment in this population.